Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis

Abstract

Aims/hypothesis The evidence on the association between pioglitazone use and bladder cancer is contradictory, with many studies subject to allocation bias. The aim of our study was to examine the effect of exposure to pioglitazone on bladder cancer risk internationally across several cohorts. The potential for allocation bias was minimised by focusing on the cumulative effect of pioglitazone as the primary endpoint using a time-dependent approach.Methods Prescription, cancer and mortality data from people with type 2 diabetes were obtained from six populations across the world (British Columbia, Finland, Manchester, Rotterdam, Scotland and the UK Clinical Practice Research Datalink). A discrete time failure analysis using Poisson regression was applied separately to data from each centre to model the effect of cumulative drug exposure on bladder cancer incidence, with time-dependent adjustment for ever use of Electronic supplementary material The online version of this article (doi:10.1007/s00125-014-3456-9) contains peer-reviewed but unedited supplementary material, which is available to authorised users. -014-3456-9 pioglitazone. These were then pooled using fixed and random effects meta-regression. Results Data were collated on 1.01 million persons over 5.9 million person-years. There were 3,248 cases of incident bladder cancer, with 117 exposed cases and a median follow-up duration of 4.0 to 7.4 years. Overall, there was no evidence for any association between cumulative exposure to pioglitazone and bladder cancer in men (rate ratio [RR] per 100 days of cumulative exposure, 1.01; 95% CI 0.97, 1.06) or women (RR 1.04; 95% CI 0.97, 1.11) after adjustment for age, calendar year, diabetes duration, smoking and any ever use of pioglitazone. No association was observed between rosiglitazone and bladder cancer in men (RR 1.01; 95% CI 0.98, 1.03) or women (RR 1.00; 95% CI 0.94, 1.07). Conclusions/interpretation The cumulative use of pioglitazone or rosiglitazone was not associated with the incidence of bladder cancer in this large, pooled multipopulation analysis.Diabetologia (2015) 58:493-504 DOI 10.1007/s00125

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

“…However, Gale has argued that pioglitazone could be acting as a growth promoter in latent tumours. 40 A very large study by Levin et al, 41 mainly in the UK, Finland and British Columbia (one million people with type 2 diabetes, almost 6 million person-years of observation), found no increased risk of bladder cancer, providing further reassurance.…”

Epidemiology of urothelial carcinoma

“…With a median follow-up period of 4-7.4 years, there was no association between cumulative exposure to pioglitazone or rosiglitazone and bladder cancer after adjusting for age, calendar year, duration of diabetes, and smoking history. 46 …”

Metformin in advanced chronic kidney disease: are current guidelines overly restrictive?

“…9 Other drugs such as the dipeptidylpeptidase-4 inhibitors lack long-term and hard outcome data, whilst pioglitazone has been associated with heart failure and bladder cancer (although a recent pooled analysis has challenged the latter). 46,47 Therefore, when metformin is contraindicated, the alternative is often to switch to a sulphonylurea or insulin. Both of these are associated with weight gain, an important side-effect that has implications for both body image and cardiovascular risk.…”